METABOLIC AND IMMUNOLOGICAL FEATURES OF THE FAILING ISLET TRANSPLANTED PATIENT

  1. Paolo Fiorina, MD, PhD1,,2,
  2. Andrea Vergani, MD1,,2,
  3. Alessandra Petrelli, MD1,
  4. Francesca D'Addio, MD2,
  5. Lucilla Monti, MD1,
  6. Reza Abdi, MD2,
  7. Emanuele Bosi, MD1,
  8. Paola Maffi, MD1 and
  9. Antonio Secchi, MD (antonio.secchi{at}hsr.it)1,,3
  1. 1Medicine, San Raffaele Scientific Institute and
  2. 3Università Vita e Salute-San Raffaele, Milan; Italy
  3. 2Transplantation Research, Children's Hospital/Brigham and Women's Hospital, Boston

    Abstract

    Objective: This retrospective study was designed to identify metabolic and immune predictors of early islet allograft failure.

    Research Design and Methods: We measured several metabolic and immunological markers at the time of pre-transplant and several time points post-transplantation in 17 patients with long-term functioning graft (Long fx) and 20 patients with short-term functioning graft (Short fx).

    Results: The Short fx group, but not the Long fx one, showed higher insulin resistance, altered pro-insulin processing, lower sIL2-r (marker of T cell activation), and higher sFasL (marker of apoptosis) during the entire follow-up particularly at time of failure.

    Conclusions: Patients who experienced an early failure of islet allograft showed specific metabolic and immunological signs long before islet failure.

    Footnotes

      • Received September 18, 2007.
      • Accepted November 29, 2007.

    This Article

    1. Published online before print December 10, 2007, doi: 10.2337/dc07-1831
    1. » Abstract
    2. Full Text (PDF)
    3. Online-Only Appendix
    4. Online-Only Appendix
    5. All Versions of this Article:
      1. dc07-1831v1
      2. 31/3/436most recent

    Current Issue

    1. December 2009, 32 (12)
    1. Current Issue
    1. Alert me to new issues of Diabetes Care